ai&
ai& and Tenstorrent jointly launched JapanFold on September 3, 2026, a drug discovery platform that serves open-source structural biology models on ai&'s sovereign infrastructure running on Tenstorrent Galaxy superclusters, with every computation executing inside Japan. The companies describe it as ai&'s first substant JapanFold catalogs models across three areas: structure and binding affinity prediction (Boltz-2, OpenFold3, ESMFold-2, OpenDDE, Protenix-v2, RoseTTAFold3, OpenBind-0, Nesso-1), de novo drug design (BoltzGen, RFdiffusion 3, PXDesign), and protein embeddings (ESMC, SaProt). Access is available via a no-install browser W